{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:11:20Z","timestamp":1790845880325,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T00:00:00Z","timestamp":1423008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In an effort to develop potent antidepressant agents, new pyrazoline derivatives 2a\u2013s were synthesized and evaluated for their antidepressant-like activity by tail suspension test (TST) and modified forced swimming test (MFST). The effects of the compounds on spontaneous locomotor activity were also investigated using an activity cage apparatus. Among these derivatives, compounds 2b, 2d, 2f, 2o, and 2r decreased both horizontal and vertical activity number of the mice. On the other hand, compounds 2a, 2h, 2j, 2k, 2l, 2m, and 2n, which did not induce any significant change in the locomotor activity, significantly shortened the immobility time of mice in TST and MFST, representing the presence of the antidepressant-like effect. Additionally, the same compounds increased the swimming time of mice in MFST without any change in climbing duration, similar to the reference drug fluoxetine (10 mg\/kg). In the light of previous papers examining the effects of pyrazolines on central nervous system, this study, once more, pointed out remarkable antidepressant activity potential of pyrazoline derivatives.<\/jats:p>","DOI":"10.3390\/molecules20022668","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T08:25:00Z","timestamp":1423038300000},"page":"2668-2684","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Synthesis and Evaluation of New 1,5-Diaryl-3-[4-(methyl-sulfonyl)phenyl]-4,5-dihydro-1H-pyrazole Derivatives as Potential Antidepressant Agents"],"prefix":"10.3390","volume":"20","author":[{"given":"Ahmet","family":"\u00d6zdemir","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University,  26470 Eski\u015fehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehlika","family":"Alt\u0131ntop","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University,  26470 Eski\u015fehir, Turkey"},{"name":"Graduate School of Health Sciences, Anadolu University, 26470 Eski\u015fehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-0923","authenticated-orcid":false,"given":"Zafer","family":"Kaplanc\u0131kl\u0131","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University,  26470 Eski\u015fehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Anadolu University, 26470 Eski\u015fehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcmide","family":"Demir \u00d6zkay","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Anadolu University, 26470 Eski\u015fehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclhan","family":"Turan-Zitouni","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University,  26470 Eski\u015fehir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/NDT.S41387","article-title":"Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder","volume":"10","author":"Alvarez","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/17460441.2014.907790","article-title":"Fluoxetine: A case history of its discovery and preclinical development","volume":"9","author":"Bravo","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17460441.2014.892071","article-title":"Fresh approaches to antidepressant drug discovery","volume":"9","author":"Anacker","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/17460441.2013.830102","article-title":"New design strategies for antidepressant drugs","volume":"8","author":"Immadisetty","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/cn3001125","article-title":"Future directions for serotonin and antidepressants","volume":"4","author":"Artigas","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.2174\/092986711797636090","article-title":"The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant\/anticonvulsant agents","volume":"18","author":"Secci","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/1389557511313060012","article-title":"Pyrazolines: A biological review","volume":"13","author":"Marella","year":"2013","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543776.2012.667403","article-title":"Recent advances in the therapeutic applications of pyrazolines","volume":"22","author":"Shaaban","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/14756366.2013.795956","article-title":"4,5-Dihydro-1H-pyrazole: an indispensable scaffold","volume":"29","author":"Alex","year":"2014","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1871524914666140129122632","article-title":"Pyrazoline: A promising scaffold for the inhibition of monoamine oxidase","volume":"13","author":"Mathew","year":"2013","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.bmcl.2005.08.040","article-title":"Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxy naphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines","volume":"15","author":"Prasoona","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejmech.2006.09.006","article-title":"Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives","volume":"42","author":"Kandilci","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bmc.2008.11.068","article-title":"New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity","volume":"17","author":"Ozgen","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s12272-009-1915-5","article-title":"Effects of some 1,3,5-trisubstitued-2-pyrazoline derivatives on depression and anxiety parameters of mice","volume":"32","author":"Can","year":"2009","journal-title":"Arch. Pharm. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00044-009-9176-x","article-title":"Evaluation of antidepressant-like effect of 2-pyrazoline derivatives","volume":"19","author":"Demet","year":"2010","journal-title":"Med. Chem. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.ejmech.2010.06.011","article-title":"New pyrazoline derivatives and their antidepressant activity","volume":"45","author":"Altintop","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.bmc.2005.11.041","article-title":"Design, synthesis, and biological evaluation of 1,3-diarylprop-2-en-1-ones: A novel class of cyclooxygenase-2 inhibitors","volume":"14","author":"Zarghi","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejphar.2012.10.017","article-title":"Anti-depressant-like effect of vitexin in BALB\/c mice and evidence for the involvement of monoaminergic mechanisms","volume":"699","author":"Can","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: Recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pnpbp.2011.08.015","article-title":"Antidepressant-like effect of Valeriana glechomifolia Meyer (Valerianaceae) in mice","volume":"36","author":"Salles","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.brainresbull.2008.08.012","article-title":"Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice","volume":"77","author":"Tanaka","year":"2008","journal-title":"Brain Res. Bull."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/2\/2668\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:42:21Z","timestamp":1760215341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/20\/2\/2668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,4]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2]]}},"alternative-id":["molecules20022668"],"URL":"https:\/\/doi.org\/10.3390\/molecules20022668","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,4]]}}}